Researchers unveil a novel strategy for identifying key proteins in organelle communication

Gilead will scrap one of three Phase III tri­als for ma­grolimab, the an­ti-CD47 drug at the heart of its $4.9 bil­lion ac­qui­si­tion of Forty Sev­en

What makes a great biotech start­up? Every year, the End­points 11 awards try to an­swer that ques­tion. We’ve spent the last sev­er­al months ex­am­in­ing dozens